BioCentury
ARTICLE | Clinical News

Obinutuzumab regulatory update

November 19, 2012 8:00 AM UTC

The European Commission granted Orphan Drug designation for obinutuzumab from Roche to treat chronic lymphocytic leukemia (CLL). The humanized mAb against CD20 is in Phase III testing for CLL, non-Ho...